Screener
Ocular Therapeutix OCUL Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Ocular Therapeutix in its filing.
Tagged under the XBRL concept us-gaap:LongTermNotesPayable.
The source filing: Ocular Therapeutix’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 7:28 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055256
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease liabilities, net of current portion | 4,230 | 2,815 |
| Derivative liability | 12,071 | 13,903 |
| Deferred revenue | 14,000 | 14,000 |
| Notes payable, net | 72,062 | 71,336 |
| Other non-current liabilities | 909 | 887 |
| Total liabilities | 150,955 | 153,747 |
| Commitments and contingencies (Note 14) | ||
| Stockholders’ equity: |
Item 1. Financial Statements (unaudited)
FAQ
- What is Ocular Therapeutix's long-term debt?
- Ocular Therapeutix (OCUL) reported long-term debt of $72.06M in Q1 2026.
- How has Ocular Therapeutix's long-term debt changed year-over-year?
- Ocular Therapeutix's long-term debt increased by 4.1% year-over-year, from $69.2M to $72.06M.
- What is the long-term trend for Ocular Therapeutix's long-term debt?
- Over 5 years (2020 to 2025), Ocular Therapeutix's long-term debt has grown at a 33.3% compound annual growth rate (CAGR), from $16.94M to $71.34M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Ocular Therapeutix's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude